Patients harboring BRAF mutations or dysregulation of the MAPK and PI3K pathways, particularly those with low-grade serous ovarian carcinoma, may significantly benefit from BRAF or MEK inhibitors [5]. This evidence concerns the gene BRAF and ovarian serous carcinoma.